Table 2.
Details of 12 patients with HBV reactivation.
| Baseline | At reactivation | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| NO. | Age (years) |
Gender | HBV DNA IU/ml |
HBsAg | Antiviral prophylaxis |
Intervals (months) |
TACE (frequency) |
HBV DNA IU/ml |
HBsAg | Antiviral treatment |
| 1 | 35 | M | Undetectable | + | ETV | 17.5 | 6 | 2130 | + | ETV |
| 2 | 50 | M | Undetectable | + | / | 15.0 | 6 | 688 | + | ETV |
| 3 | 63 | M | Undetectable | + | / | 2.8 | 3 | 107 | + | ETV |
| 4 | 49 | M | Undetectable | + | ETV | 4.2 | 3 | 3160 | + | TAF |
| 5 | 71 | M | Undetectable | + | / | 12.0 | 7 | 553 | + | ETV |
| 6 | 47 | M | Undetectable | + | / | 9.9 | 8 | 512 | + | ETV |
| 7 | 54 | M | Undetectable | + | / | 8.1 | 4 | 1240 | + | ETV |
| 8 | 72 | M | Undetectable | – | / | 2.5 | 2 | 31 | – | ETV |
| 9 | 66 | M | Undetectable | – | / | 1.9 | 2 | 113 | – | ETV |
| 10 | 53 | M | Undetectable | + | / | 2.6 | 2 | 639 | + | / |
| 11 | 19 | F | Undetectable | + | ETV | 6.9 | 2 | 153 | + | ETV |
| 12 | 64 | M | 173 | + | ETV | 4.4 | 1 | 38800 | + | ETV |
ETV, entecavir; F, female; HBsAg, hepatitis B surface antigen; M, male; NO., number; TACE, transarterial chemoembolization; TAF, tenofovir alafenamide fumarate.